Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H H van der Zee

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The British Journal of Dermatology|January 19, 2019
The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo studyA R J V Vossen, C B Ardon, H H van der Zee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 19, 2023
Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativaP Aarts, J C van Huijstee, H H van der Zee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2012
Depression in patients with hidradenitis suppurativaA J Onderdijk, H H van der Zee, S Esmann, et al.
The British Journal of Dermatology|February 22, 2011
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1βH H van der Zee, L de Ruiter, D G van den Broecke, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2018
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkersA R J V Vossen, H H van der Zee, N Davelaar, et al.
The British Journal of Dermatology|September 21, 2011
Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesionsH H van der Zee, L de Ruiter, J Boer, et al.
Frontiers in Immunology|October 10, 2022
Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander?K R van Straalen, K Dudink, P Aarts, et al.
The British Journal of Dermatology|August 19, 2016
Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional studyI C Janse, I E Deckers, A D van der Maten, et al.
The British Journal of Dermatology|December 5, 2018
Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessmentA Rondags, K R van Straalen, J R van Hasselt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2020
A novel nicastrin mutation in a three-generation Dutch family with hidradenitis suppurativa: a search for functional significanceA R J V Vossen, K R van Straalen, S M A Swagemakers, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The British Journal of Dermatology|January 19, 2019
The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo studyA R J V Vossen, C B Ardon, H H van der Zee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 19, 2023
Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativaP Aarts, J C van Huijstee, H H van der Zee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2012
Depression in patients with hidradenitis suppurativaA J Onderdijk, H H van der Zee, S Esmann, et al.
The British Journal of Dermatology|February 22, 2011
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1βH H van der Zee, L de Ruiter, D G van den Broecke, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2018
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkersA R J V Vossen, H H van der Zee, N Davelaar, et al.
The British Journal of Dermatology|September 21, 2011
Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesionsH H van der Zee, L de Ruiter, J Boer, et al.
Frontiers in Immunology|October 10, 2022
Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander?K R van Straalen, K Dudink, P Aarts, et al.
The British Journal of Dermatology|August 19, 2016
Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional studyI C Janse, I E Deckers, A D van der Maten, et al.
The British Journal of Dermatology|December 5, 2018
Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessmentA Rondags, K R van Straalen, J R van Hasselt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2020
A novel nicastrin mutation in a three-generation Dutch family with hidradenitis suppurativa: a search for functional significanceA R J V Vossen, K R van Straalen, S M A Swagemakers, et al.
Pageof 3